Combating the ageing process

20 February 2004

Strip out Sanofi s contribution, hedging gains and the reintegration of provisions, and the picture looks a lot less rosy. With L Oreal s core business trading at 30 times this year s earnings, the premium to rivals looks too steep.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)